公开(公告)号：HU226108B1

公开(公告)日：2008-04-28

申请号：HU9701984

申请日：1997-11-12

Applicant: HOECHST AG

Inventor： ENGLERT HEINRICH CHRISTIAN DR ,  GERLACH UWE DR ,  GOEGELEIN HEINZ DR ,  KLAUS ERIK DR ,  LINZ WOLFGANG DR ,  MANIA DIETER DR

IPC: C07D311/04 ,  C07D311/58 ,  A61K31/35 ,  A61K31/352 ,  A61K31/353 ,  A61K31/355 ,  A61K31/40 ,  A61K31/4025 ,  A61P9/00 ,  A61P9/06 ,  C07D207/26 ,  C07D209/34 ,  C07D211/76 ,  C07D217/24 ,  C07D227/02 ,  C07D311/16 ,  C07D311/18 ,  C07D311/42 ,  C07D311/70 ,  C07D405/12

Abstract: 3-Amido-chromanylsulphonyl-urea or -thiourea derivatives of formula (I), in all stereoisomer (or mixture) forms, and their salts are new. R1 = H, alkyl, alkoxy, alkoxyalkoxy, alkylthio, F, Cl, Br, I or CF3; R2 = H, Me or Et; R3 = H or alkyl; Z = O or S; A = phenyl (optionally substituted by 1-3 halo, Me, Et, OMe or OEt), lactam residue of formula (i), 1-oxo-1,2,3,4-tetrahydroisoquinolin-2-yl, 1-oxo-perhydroisoquinolin-2-yl, 1-oxo-2,3-isoindolin-2-yl or 1-oxo-perhydroisoindolin-2-yl; B = 3-6C alkylene or 3-6C alkenylene (both optionally substituted by 1-3 alkyl); all alkyl moieties have 1-4C.

公开(公告)号：DK0503162T3

公开(公告)日：1998-12-07

申请号：DK91122406

申请日：1992-01-01

Applicant: HOECHST AG

Inventor： WAGNER ADALBERT DR ,  ENGLERT HEINRICH DR ,  KLEEMANN HEINZ-WERNER DR ,  GERHARDS HERMANN DR ,  SCHOELKENS BERNWARD PROF DR ,  BECKER REINHARD DR ,  LINZ WOLFGANG DR ,  CAILLE JEAN-CLAUDE ,  VEVERT JEAN-PAUL

IPC: A61K31/40 ,  A61K31/415 ,  A61K31/425 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/445 ,  A61K31/505 ,  A61K31/535 ,  A61K31/54 ,  A61K31/64 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P13/02 ,  A61P15/00 ,  A61P43/00 ,  C07D207/34 ,  C07D207/36 ,  C07D233/54 ,  C07D233/66 ,  C07D233/68 ,  C07D233/70 ,  C07D233/84 ,  C07D233/90 ,  C07D249/02 ,  C07D255/02 ,  C07D257/02 ,  C07D257/04 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D453/02 ,  C07D521/00

Abstract: Azole derivative of the general formula (I) in which A, L, O, R , X, Y, Z and q have the meanings given, a process for their preparation, pharmaceutical preparations and the use of the compounds are described. Azole derivatives of the formula I where the symbols have, for example, the following meanings: R = (C2-C10)-alkyl Z = nitrogen X and Y = independently of one another CR L = -CH2- q = zero or 1 A = biphenyl radical which is substituted, for example, by R R = halogen or hydrogen R = SO2-NH-CO-OR and R = phenyl, are highly active antagonists of angiotensin II receptors.

公开(公告)号：DE19712636A1

公开(公告)日：1998-10-01

申请号：DE19712636

申请日：1997-03-26

Applicant: HOECHST AG

Inventor： LANG HANS JOCHEN DR ,  JANSEN HANS-WILLI DR ,  SCHWARK JAN-ROBERT DR ,  KLEEMANN HEINZ-WERNER DR ,  JUNG OLIVER ,  SCHAEFER HANS-LUDWIG DR ,  LINZ WOLFGANG DR ,  KRAMER WERNER PROF DR DR ,  SCHOELKENS BERNWARD PROF DR ,  FALK EUGEN DR

IPC: A61K31/166 ,  A61K31/155 ,  A61K31/415 ,  A61K31/42 ,  A61K31/425

Abstract: Use of sodium/proton exchange inhibitors in the preparation of a medicament for treatment of raised blood lipid levels is new.

公开(公告)号：ES2104971T3

公开(公告)日：1997-10-16

申请号：ES93101840

申请日：1993-02-05

Applicant: HOECHST AG

Inventor： ENGLERT HEINRICH DR ,  MANIA DIETER DR ,  LANG HANS-JOCHEN DR ,  SCHOLZ WOLFGANG DR ,  LINZ WOLFGANG DR ,  ALBUS UDO DR

IPC: A61K31/155 ,  A61K31/165 ,  A61K31/445 ,  A61P1/16 ,  A61P3/08 ,  A61P3/10 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P13/02 ,  A61P15/00 ,  A61P35/00 ,  C07C279/22 ,  C07D213/65 ,  C07D295/14 ,  C07D295/155

Abstract: There are described benzoylguanidines of the formula I in which R(1) or R(2) is an amino group -NR(3)R(4), where R(3) and R(4) are equal to H, (cyclo)alkyl or R(3) is equal to phenyl-(CH2)p- where p = 0, 1, 2, 3 or 4, or phenyl, or R(3) and R(4) together can also be a methylene chain, and in which the other substituent R(1) or R(2) in each case is H, F, Cl, alkyl, alkoxy, CF3, CmF2m+1-CH2-, benzyl or phenoxy, and their pharmaceutically tolerable salts. The compounds according to the invention have very good antiarrhythmic properties, such as they show, for example, in the case of oxygen deficiency symptoms. The compounds are used as antiarrhythmic medicaments having a cardioprotective component for infarct prophylaxis and infarct treatment and also for the treatment of angina pectoris, where they preventively inhibit or strongly decrease the pathophysiological processes during the formation of ischaemically induced damage, in particular during the induction of ischaemically induced cardiac arrhythmias.

公开(公告)号：DE19546736A1

公开(公告)日：1997-06-19

申请号：DE19546736

申请日：1995-12-14

Applicant: HOECHST AG

Inventor： ENGLERT HEINRICH CHRISTIAN DR ,  GERLACH UWE DR ,  MANIA DIETER DR ,  LINZ WOLFGANG DR ,  GOEGELEIN HEINZ DR ,  KLAUS ERIK DR ,  CRAUSE PETER DR

IPC: C07D311/58 ,  A61K31/35 ,  A61K31/352 ,  A61K31/353 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/4025 ,  A61K31/4412 ,  A61K31/443 ,  A61K31/445 ,  A61P9/00 ,  A61P9/06 ,  A61P9/10 ,  C07D311/64 ,  C07D311/70 ,  C07D405/12 ,  C07D311/60 ,  C07D227/087 ,  A61K31/44

Abstract: N-(4-Amidoalkyl-chroman-5-yl-sulphonyl)-urea or -thiourea derivatives of formula (I) and their salts are new. R1 = H, alkyl, alkoxy, F, Cl, Br, I, CF3, NH2, mono- or dialkylamino or alkylthio; R2a = H, Me or Et; R2b, R2d = H, Me or Et; or phenyl or benzyl (both optionally ring-substituted by 1-3 of halogen, Me, Et, OMe and OEt); R2c,R2e = H, Me or Et; R3 = H, alkyl, cycloalkyl, cycloalkylmethyl or CF3; n = 1 or 2; Z = O or S; A = phenyl (optionally substituted by 1-3 of halogen, Me, OMe, Et or OEt), a lactam residue of formula (a), 1-oxo-1,2,3,4-tetrahydroisoquinolin-2-yl, 1-oxo-per-hydro-isoquinolin-2-yl, 1-oxo-1,2-dihydro-iso-indol-2-yl or 1-oxo-per-hydro-iso-indol-2-yl; B = 3-6C alkylene or 3-6C alkenylene (both optionally substituted by 1-3 alkyl); unless specified otherwise alkyl moieties have 1-4C and cycloalkyl moieties 3-6C.

公开(公告)号：ES2086341T3

公开(公告)日：1996-07-01

申请号：ES90117400

申请日：1990-09-10

Applicant: HOECHST AG

Inventor： HEITSCH HOLGER DR ,  HENNING RAINER DR ,  LINZ WOLFGANG DR ,  NICKEL WOLF-ULRICH DR ,  RUPPERT DIETER DR ,  URBACH HANSJORG DR

IPC: A61K31/44 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/445 ,  A61P9/12 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07K5/02

Abstract: The invention relates to renin-inhibiting amino-acid derivatives of the formula in which R is a radical of a substituted nitrogen-containing heterocycle such as piperidine, X is CO, CS, SO2 or SO, Y is CH2, O or S, B is the residue of an amino acid of the formula H-B-OH, and R , R and R are as defined in the description, process for their preparation, agents containing them and their use.

公开(公告)号：GR3019331T3

公开(公告)日：1996-06-30

申请号：GR960400719

申请日：1996-03-15

Applicant: HOECHST AG

Inventor： HEITSCH HOLGER DR ,  HENNING RAINER DR ,  LINZ WOLFGANG DR ,  NICKEL WOLF-ULRICH DR ,  RUPPERT DIETER DR ,  URBACH HANSJOERG DR

IPC: A61K31/44 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/445 ,  A61P9/12 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07K5/02

Abstract: The invention relates to renin-inhibiting amino-acid derivatives of the formula in which R is a radical of a substituted nitrogen-containing heterocycle such as piperidine, X is CO, CS, SO2 or SO, Y is CH2, O or S, B is the residue of an amino acid of the formula H-B-OH, and R , R and R are as defined in the description, process for their preparation, agents containing them and their use.

公开(公告)号：AT135368T

公开(公告)日：1996-03-15

申请号：AT90117400

申请日：1990-09-10

Applicant: HOECHST AG

Inventor： HEITSCH HOLGER DR ,  HENNING RAINER DR ,  LINZ WOLFGANG DR ,  NICKEL WOLF-ULRICH DR ,  RUPPERT DIETER DR ,  URBACH HANSJOERG DR

IPC: A61K31/44 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/445 ,  A61P9/12 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07K5/02

Abstract: The invention relates to renin-inhibiting amino-acid derivatives of the formula in which R is a radical of a substituted nitrogen-containing heterocycle such as piperidine, X is CO, CS, SO2 or SO, Y is CH2, O or S, B is the residue of an amino acid of the formula H-B-OH, and R , R and R are as defined in the description, process for their preparation, agents containing them and their use.

公开(公告)号：DE59008959D1

公开(公告)日：1995-06-01

申请号：DE59008959

申请日：1990-09-03

Applicant: HOECHST AG

Inventor： ENGLERT HEINRICH CHRISTIAN DR ,  LANG HANS-JOCHEN DR ,  LINZ WOLFGANG DR ,  SCHOELKENS BERNWARD PROF DR ,  SCHOLZ WOLFGANG DR

IPC: C07C279/22 ,  A61K31/155 ,  A61K31/18 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/445 ,  A61K31/455 ,  A61K31/535 ,  A61K31/5375 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  C07C277/00 ,  C07C279/10 ,  C07C311/15 ,  C07C311/47 ,  C07C317/42 ,  C07C317/44 ,  C07C323/60 ,  C07C323/62 ,  C07C323/65 ,  C07C323/67 ,  C07D209/08 ,  C07D211/28 ,  C07D295/14 ,  C07D295/155 ,  C07D295/195 ,  C07D295/22 ,  C07D295/26

Abstract: Benzoylguanidines of the formula I (* CHEMICAL STRUCTURE *) (I) where R(1) or R(2) is equal to R(6)-S(O)n- or R(7)R(8)N-O2S- and the other substituent R(1) or R(2) is in each case equal to H, F, Cl, Br, I, alkyl, alkoxy or phenoxy, R(6)-S(O)n or R(7)R(8)N- and R(6) is equal to alkyl, cycloalkyl, cyclopentylmethyl, cyclohexylmethyl or phenyl, R(7) and R(8) are equal to alkyl or phenylalkyl or phenyl, and in which R(7) and R(8) may also together be a C4-C7 chain, and in which R(7) and R(8), together with the nitrogen atom to which they are bonded, may be a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system, and where R(3), R(4) and R(5) are equal to hydrogen or alkyl, or R(3) and R(4) are together an alkylene chain or R(4) and R(4) are together an alkylene chain, and where n is equal to zero, 1 or 2 and their pharmaceutically tolerable salts are outstanding antiarrhythmics.

公开(公告)号：AT121738T

公开(公告)日：1995-05-15

申请号：AT90116859

申请日：1990-09-03

Applicant: HOECHST AG

Inventor： ENGLERT HEINRICH CHRISTIAN DR ,  LANG HANS-JOCHEN DR ,  LINZ WOLFGANG DR ,  SCHOELKENS BERNWARD PROF DR ,  SCHOLZ WOLFGANG DR

IPC: C07C279/22 ,  A61K31/155 ,  A61K31/18 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/445 ,  A61K31/455 ,  A61K31/535 ,  A61K31/5375 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  C07C277/00 ,  C07C279/10 ,  C07C311/15 ,  C07C311/47 ,  C07C317/42 ,  C07C317/44 ,  C07C323/60 ,  C07C323/62 ,  C07C323/65 ,  C07C323/67 ,  C07D209/08 ,  C07D211/28 ,  C07D295/14 ,  C07D295/155 ,  C07D295/195 ,  C07D295/22 ,  C07D295/26

Abstract: Benzoylguanidines of the formula I (* CHEMICAL STRUCTURE *) (I) where R(1) or R(2) is equal to R(6)-S(O)n- or R(7)R(8)N-O2S- and the other substituent R(1) or R(2) is in each case equal to H, F, Cl, Br, I, alkyl, alkoxy or phenoxy, R(6)-S(O)n or R(7)R(8)N- and R(6) is equal to alkyl, cycloalkyl, cyclopentylmethyl, cyclohexylmethyl or phenyl, R(7) and R(8) are equal to alkyl or phenylalkyl or phenyl, and in which R(7) and R(8) may also together be a C4-C7 chain, and in which R(7) and R(8), together with the nitrogen atom to which they are bonded, may be a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system, and where R(3), R(4) and R(5) are equal to hydrogen or alkyl, or R(3) and R(4) are together an alkylene chain or R(4) and R(4) are together an alkylene chain, and where n is equal to zero, 1 or 2 and their pharmaceutically tolerable salts are outstanding antiarrhythmics.